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Department of Dermatology and Allergy, Clinical Research Center for Hair and Skin Science, Charité-Universitätsmedizin Berlin, GermanyAlopecia areata (AA) is an autoimmune disease due to T cell attack of observation made in a special patient is complemented with mechanis-
the hair follicles and breakdown of their immune privilege resulting in
transient non-scarring hair loss which may last from weeks to decades
and which presents an enormous psychological burden. As so far no
FDA approved successful treatments for AA are available, new hope
and light arose on the horizon with the recently published genome
wide association studies in AA patients revealing new molecular path-
ways disrupted in AA including autophagy/apoptosis, transforming
growth factor beta/Tregs and JAK (Janus family of non-receptor protein
tyrosine kinase) signaling (Petukhova et al., 2010; Betz et al., 2015).
Thus, today it is assumed that CD8 + NKG2D+ T effector memory
cells mediate alopecia areata in part through Janus kinase (JAK) signal-
ing and that alopecia areata might be treated with JAK inhibitors. This
assumption has been supported by clinical use of JAK inhibitors within
a clinical study setting (Xing et al., 2014) or observed as a “side effect”,
when JAK inhibitor treatment of another underlying disease resulted
in regrowth of longstanding patchy or universal alopecia areata
(Craiglow and King, 2014; Pieri et al, 2015). Xing et al., 2014 demon-
strated that the interferon-γ (IFNγ)-signaling pathway is upregulated
in AA-lesional skin, and that the use of JAK inhibitorswas able to reverse
symptoms of the disorder in mice and in three humans with AA. While
different groups (Craiglow and King, 2014; Pieri et al, 2015; Higgins
et al, 2015) reported successful use of ruxolitinib, a JAK1/2 inhibitor li-
censed for treating myeloﬁbrosis, others reported successful use of the
JAK 1/3 inhibitor tofacitinib in AA while using it for treating psoriasis
(Craiglow and King, 2014).
In this issue of EBioMedicine, Jabbari et al. followeduponhair growth
observed in a patient under baricitinib therapy, also a JAK1/2 inhibitor
and studied JAK inhibitor action in the C3H/HeJ graft-recipient mouse
model of AA (Jabbari et al., 2015). Under JAK inhibitor treatment,
CD8+ cell inﬁltrates and MHC class I and II expressions were markedly
reduced in C3H/HeJmice graftedwith alopecic skin, both in a preventive
and a therapeutic setting. In addition, gene expression proﬁling using
the Alopecia Areata Disease Activity Index (ALADIN) biomarker for re-
sponse to treatment conﬁrmed the assumed normalization of the IFN-
gamma gene expression signature. The approach of Jabbari et al. repre-
sents an excellentmodel for translational work, where a speciﬁc clinicalDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.02.015.
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histochemistry and gene expression proﬁles with the current idea of
how JAK inhibitors could be beneﬁcial in AA (Jabbari et al., 2015).
However, all euphoria should not let forget that JAK inhibitors inhib-
it multiple pathogenic pathways simultaneously. A broad spectrum of
side effects already limits their use in the different licensed indications.
Similarly, clinical studies on response rates in larger groups of patients
will have to take into account the heterogeneity among AA patients.
Maintenance of hair growth and relapse rates after cessation of therapy
will have to be monitored carefully. Also, we have to be very aware of
the fact that despite its tremendous psychosocial burden, AA is a benign
lifelong genetic predisposition, with one third of AA patients being af-
fected before 30 years of age. Safety aspects will have to be carefully
considered especially in this young population. With this regard, the
small molecule JAK inhibitors do not only offer advantages for effective
oral delivery, but are also highly interesting candidate molecules for
topical treatment. While overall penetration rates in skin especially via
the transfollicular route should not be a problem, a focus of research
should be put onways to increase follicular penetration and reduce sys-
temic absorption. Incorporation in particle-based formulations or even
the design of functionalized nanocarriers capable of targeting inﬂam-
matory inﬁltrates along the hair follicle could be one option for future
developments in AA management strategies. Such targeted delivery
may help increase local drug concentration and efﬁcacy with reduced
systemic side-effects.
This translational exemplary research may pave the way to further
target-oriented strategies based on insights in the disease pathogenesis
rather than empiric observation, even in such complex autoimmune
mediated diseases as alopecia areata.Conﬂict of Interest
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